Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind.

Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating.

The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mount Sinai Hospital, Canada
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with newly diagnosed NAION (within the past 30 days but preferably within the first 14).

Exclusion Criteria:

• Patients who are unable to give informed consent

• Patient with:

• uncontrolled glaucoma

• pregnancy

• lactation

• proliferative diabetic retinopathy

• active clinically significant diabetic macular edema

• active uveitis

• prior treatment with intraocular steroids that incited significant increase in intra-ocular pressure

• other known causes of decreased visual acuity in the recently involved eye such as significant dry or wet macular degeneration

• previous history of other optic neuropathies

• previous history of ocular trauma that resulted in decreased visual acuity

• Patients with baseline amblyopia in the newly involved eye and visual acuity worse than 20/50 prior to the onset of NAION

• Previous treatment for any ocular condition with any investigational drugs